Edwards Stock Today

EW -  USA Stock  

USD 97.55  4.11  4.40%

Market Performance
0 of 100
Odds Of Distress
Less than 1
Edwards Lifesciences is selling for under 97.55 as of the 16th of May 2022; that is 4.40 percent up since the beginning of the trading day. The stock's lowest day price was 95.0. Edwards Lifesciences has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Edwards Lifesciences Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of May 2020 and ending today, the 16th of May 2022. Click here to learn more.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. The company has 624.33 M outstanding shares of which 6.32 M shares are currently sold short in the market by investors with about 2.0 days to cover all shorted shares. More on Edwards Lifesciences Corp
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Edwards Lifesciences Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Edwards Lifesciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Edwards Lifesciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Edwards Lifesciences generated a negative expected return over the last 90 days
Edwards Lifesciences is unlikely to experience financial distress in the next 2 years
Over 86.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.defenseworld.net: Michael A. Mussallem Sells 32550 Shares of Edwards Lifesciences Co. Stock - Defense World
Edwards Lifesciences Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
Edwards Lifesciences Corp SEC Filings
Edwards Lifesciences SEC Filings Security & Exchange Commission EDGAR Reports
ChairmanMichael Mussallem  (View All)
Thematic Classifications
Active investing themes Edwards currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Showing 3 out of 4 themes
Average Analyst Recommendation
Analysts covering Edwards Lifesciences report their recommendations after researching Edwards Lifesciences' financial statements, talking to executives and customers, or listening in on Edwards Lifesciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Edwards Lifesciences Corp. The Edwards consensus assessment is calculated by taking the average forecast from all of the analysts covering Edwards Lifesciences.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Edwards Lifesciences Corp based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Edwards Lifesciences Corp financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 5 - HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares599.9 M623.3 M
Sufficiently Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted610.2 M631.2 M
Sufficiently Down
Decreasing
Slightly volatile
Net Cash Flow from Operations1.4 B1.7 B
Significantly Down
Increasing
Slightly volatile
Total Assets7.2 B8.5 B
Fairly Down
Increasing
Slightly volatile
Total Liabilities2.5 B2.7 B
Significantly Down
Increasing
Slightly volatile
Current AssetsB3.2 B
Notably Down
Increasing
Slightly volatile
Current Liabilities942.7 MB
Significantly Down
Increasing
Slightly volatile
Total Debt713 M690.3 M
Sufficiently Up
Increasing
Slightly volatile
Return on Average Assets0.190.191
Slightly Down
Increasing
Stable
Gross Margin0.830.761
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.650.664
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Edwards Lifesciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Edwards Lifesciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Edwards Lifesciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Edwards Lifesciences' financial leverage. It provides some insight into what part of Edwards Lifesciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Edwards Lifesciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Edwards Lifesciences deploys its capital and how much of that capital is borrowed.
Liquidity
Edwards Lifesciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company reports 690.3 M of total liabilities with total debt to equity ratio (D/E) of 0.12, which may suggest the company is not taking enough advantage from financial leverage. Edwards Lifesciences Corp has a current ratio of 3.02, indicating that it is in good position to pay out its debt commitments in time. Debt can assist Edwards Lifesciences until it has trouble settling it off, either with new capital or with free cash flow. So, Edwards Lifesciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edwards Lifesciences Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edwards to invest in growth at high rates of return. When we think about Edwards Lifesciences' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

1.4 BillionShare
Edwards Lifesciences Corp (EW) is traded on New York Stock Exchange in USA. It is located in One Edwards Way and employs 15,700 people. Edwards Lifesciences is listed under Medical Equipment category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with market capitalization of 59.12 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Edwards Lifesciences's market, we take the total number of its shares issued and multiply it by Edwards Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Edwards Lifesciences Corp is active under Healthcare sector as part of Medical Devices industry. The entity has 624.33 M outstanding shares of which 6.32 M shares are currently sold short in the market by investors with about 2.0 days to cover all shorted shares. Edwards Lifesciences Corp reports about 1.47 B in cash with 1.73 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.35.
Check Edwards Lifesciences Probability Of Bankruptcy
Ownership
Edwards Lifesciences holds a total of six hundred twenty-four million three hundred thirty thousand outstanding shares. The majority of Edwards Lifesciences Corp outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Edwards Lifesciences Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Edwards Lifesciences. Please pay attention to any change in the institutional holdings of Edwards Lifesciences Corp as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Edwards Ownership Details

Edwards Stock Price Odds Analysis

What are Edwards Lifesciences' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Edwards Lifesciences jumping above the current price in 90 days from now is over 95.54%. The Edwards Lifesciences Corp probability density function shows the probability of Edwards Lifesciences stock to fall within a particular range of prices over 90 days. Allowing for the 90-day total investment horizon the stock has a beta coefficient of 1.4988 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Edwards Lifesciences will likely underperform. Additionally, the company has an alpha of 0.0488, implying that it can generate a 0.0488 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Down 97.55HorizonTargetOdds Up 97.55  
4.42%90 days
 97.55 
95.54%
Based on a normal probability distribution, the odds of Edwards Lifesciences to move above the current price in 90 days from now is over 95.54 (This Edwards Lifesciences Corp probability density function shows the probability of Edwards Stock to fall within a particular range of prices over 90 days) .

Edwards Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Edwards Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Edwards Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Edwards Lifesciences' value.
InstituionSecurity TypeTotal SharesValue
Ownership Capital BvCommon Shares4.3 M506.9 M
Allspring Global Investments Holdings LlcCommon Shares2.6 M305.2 M
View Edwards Lifesciences Diagnostics

Edwards Lifesciences Historical Income Statement

Edwards Lifesciences Corp Income Statement is one of the three primary financial statements used for reporting Edwards's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Edwards Lifesciences Corp revenue and expense. Edwards Lifesciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Edwards Lifesciences Consolidated Income is fairly stable at the moment as compared to the past year. Edwards Lifesciences reported Consolidated Income of 1.5 Billion in 2021. Interest Expense is likely to climb to about 19.1 M in 2022, whereas Cost of Revenue is likely to drop slightly above 1.1 B in 2022. View More Fundamentals

Edwards Stock Against Markets

Picking the right benchmark for Edwards Lifesciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Edwards Lifesciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Edwards Lifesciences is critical whether you are bullish or bearish towards Edwards Lifesciences Corp at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Edwards Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Edwards Lifesciences Corporate Directors

Edwards Lifesciences corporate directors refer to members of an Edwards Lifesciences board of directors. The board of directors generally takes responsibility for the Edwards Lifesciences' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Edwards Lifesciences' board members must vote for the resolution. The Edwards Lifesciences board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Paul LaViolette - Independent DirectorProfile
John Cardis - Independent DirectorProfile
Wesley Schack - Presiding Independent DirectorProfile
Nicholas Valeriani - Independent DirectorProfile

Investing Edwards Lifesciences Corp

You need to understand the risk of investing before taking a position in Edwards Lifesciences. The danger of trading Edwards Lifesciences Corp is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Edwards Lifesciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Edwards Lifesciences. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Edwards Lifesciences Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Edwards Lifesciences Corp information on this page should be used as a complementary analysis to other Edwards Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Edwards Stock analysis

When running Edwards Lifesciences Corp price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Edwards Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.